 By Anita Dushyanth, PhD NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Results of the Phase 2b Trial The primary objective of the Phase II study was to explore therapeutic efficacy in patients and more importantly, determine the doses and regimen for Phase III trials. A double blind, randomized 90-day dosing trial Phase 2b, which was funded by ORMD, was designed to evaluate the efficacy of 